For a study, it was determined that irritable bowel syndrome (IBS) was a common functional gastrointestinal condition in which the microbiota showed to play a role. Probiotics were linked to a reduction in IBS symptoms in a growing number of studies, and many mechanisms of action were hypothesized. For a study, the researchers used a completely validated High Taxonomic Fingerprint Microbiota Array to characterize the intestinal microbiota of 19 people with diagnosed IBS in this investigation (HTF-Microbi. Array). It was found that the IBS microbiota differs from that of healthy people due to an imbalance in a number of commensal species, with an increase in lactobacilli, B. cereus and B. clausii, bifidobacteria, Clostridium cluster IX, and E. rectale, and a decrease in Bacteroides/Prevotella group and Veillonella genus relative abundance. In addition, the researchers found that the IBS microbiota contains higher concentrations of several bacterial species seen in the human gut microbiota, which have recently been labeled as pathobionts.  Furthermore, the researchers wanted to determine if daily administration of a novel probiotic yogurt containing B. animalis subsp lactis Bb12 and K. marxianus B0399, which has recently been shown to help with IBS symptoms, could affect the biostructure of the IBS microbiota, modulating its composition to counteract putative dysbiosis in IBS patients. Notably, the researchers revealed that the probiotic preparation’s positive effects are unrelated to major changes in the composition of the human gut microbiota.